Brolucizumab meets secondary endpoints for fluid resolution in wet AMD

A new data analysis of prespecified secondary endpoints of the phase 3 HAWK and HARRIER trials showed that retinal fluid was detected less often in patients treated with brolucizumab 6 mg compared with patients treated with aflibercept over four visits in the 36- to 48-week treatment period.
According to a press release from Novartis, this is noteworthy because “it provides insight into the effect of maintenance treatment, an important clinical focus for a chronic disease like [neovascular age-related macular degeneration].” The data were also reported at the Euretina meeting.

Full Story →